The placebo-controlled, randomized trial will include 15,000 adults in 17 countries. Volunteers for the trial are currently being recruited in Australia.
The vaccine, developed by Sanofi Pasteur, is designed to protect at-risk individuals from C. diff infections.
More Articles on Gastroenterology:
Drs. Richard Fedorak, Haili Wang Develop Urine Test for Detection of Colonic Polyps
Study: Thalidomide as Treatment for Pediatric Crohn’s Disease
6 Statistics on GI/Endoscopy Revenue Per Case in Surgery Centers by Number of ORs
